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Background
The hyperglycemia characteristic of diabetes can cause cel-
lular and tissue damage due to the biochemical alterations
that lead to the formation and accumulation of advanced
glycation end products (AGEs) [1]. Aminoguanidine (AG)
prevents the formation of AGEs by reacting with the initial
glycation products, proving to be effective in improving
proteinuria and vessel elasticity, in the prevention of dia-
betic retinopathy, and in the treatment of patients with
diabetic nephropathy [2]. Guanidine derivatives have
demonstrated various biological activities, such as antihy-
pertensive and antidiabetic effects. It has been proposed
that aminoguanidine and some of its derivatives (DAGs)
may increase sensitivity to insulin [3]. The aims of this
study were to investigate the effect of AG and two of its
derivatives (DAG11 and DAG15) on the regulation of
blood glucose and on the insulin tolerance test (ITT) in
normoglycemic and diabetic rats, and the possible toxic
effects of these derivatives.
Method
Wistar rats, 2 months of age, which had diabetes induced
by Alloxan (40 mg/kg, i.v.), and their controls were admi-
nistered the vehicle. At 21 days after the induction of
diabetes, the animals were intraperitoneally treated for
7 consecutive days with saline (SAL), AG (10 mg/kg),
DAG11 or DAG15 (10 mg/kg). On the 28th day the ani-
mals were anesthetized (ketamine, 80 mg/kg and xylazine,
12 mg/kg) and the ITT was performed with the adminis-
tration of insulin (0.75 UI/kg, i.v.) for the analysis of insu-
lin sensitivity through the glucose decay constant (klTT).
The results were expressed as mean ± SEM and were
compared using ANOVA, with Student-Newman-Keuls
post hoc test (p ≤ 0.05). The toxicological evaluation was
performed using human lymphocytes[4]. The study was
approved by the Ethics Committee for the use of animals
of the Federal University of Alagoas UFAL: 01/2012.
Results and conclusions
The basal blood glucose of the animals treated with SAL,
AG, DAG11 and DAG15 presented no significant differ-
ences. In the normoglycemic animals, although no signif-
icant difference occurred between the experimental
groups, there was an increase of 55% and 67% in the
kITT of the AG and DAG15 rats, respectively, compared
to the SAL animals. The diabetic animals treated with
AG and DAG15 presented increased (p ≤ 0.05) kITT
(150% and 81%) compared to the SAL animals. No toxic
effects were observed for any of the substances tested, at
least not in the model used. Despite having no action on
basal glucose, AG and DAG15 may be promising proto-
types for diabetes treatment drugs, in view of their
increased insulin sensitivity action in diabetic animals.
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